PLX Stock Risk & Deep Value Analysis
Protalix Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PLX Stock
We analyzed Protalix Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PLX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate-Aggressive. Here's what we found.
PLX Risk Analysis & Red Flags
What Could Go Wrong
Despite securing a $25 million milestone payment and projecting $50 million in cash, Protalix posted a TTM net loss of $6.6 million for FY 2025, with Q4 2025 revenue declining over 50% year-over-year. If the commercial ramp-up of Elfabrio underperforms expectations, or if cash burn from operations and PRX-115 development remains high, the company could face liquidity issues requiring substantial dilutive capital raises, severely impacting per-share value.
Risk Matrix
Overall
Moderate-Aggressive
Financial
Medium
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
FY 2025 TTM net loss of $6.6M, a decline from TTM profit through Q3 2025.
- ⚠
Q4 2025 revenue of $9.1M significantly down from $18.2M in Q4 2024.
- ⚠
Stock price fell 20.79% on March 18, 2026, despite positive news (EU approval, milestone payment, 2026 guidance).
- ⚠
Lack of detailed cash flow statements makes it difficult to ascertain burn rate and future funding needs beyond current projections.
Upcoming Risk Events
- 📅
Failure to meet 2026 revenue guidance ($78-$83M)
- 📅
Higher-than-expected cash burn leading to further dilution
- 📅
Negative results or delays in the PRX-115 Phase 2 trial
When to Reconsider
- 🚪
Exit if 2026 revenue guidance ($78-$83M) is significantly missed (e.g., actual revenue <$70M).
- 🚪
Sell if cash balance falls below $20M without a clear, non-dilutive funding pathway.
- 🚪
Exit if Phase 2 PRX-115 trial is halted or shows unexpected negative safety/efficacy signals.
Unlock PLX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Protalix Biotherapeutics Inc (PLX) Do?
Market Cap
$166.78M
Sector
Healthcare
Industry
Biotechnology
Employees
213
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Visit Protalix Biotherapeutics Inc WebsiteInvestment Thesis
Protalix is an attractive high-growth biotech play based on the expanding market presence of its rare disease drug Elfabrio, buoyed by recent EU approval and a significant milestone payment. Its proprietary ProCellEx platform offers a potential cost and efficacy advantage, and the Chiesi partnership provides critical commercialization muscle. While current profitability and recent market sentiment are challenging, the strong 2026 revenue guidance and pipeline progression (PRX-115) position the company for substantial long-term value creation if execution remains strong and a clear path to profitability emerges.
Is PLX Stock Undervalued?
Unlock the full AI analysis for PLX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PLX Price Targets & Strategy
12-Month Target
$6.00
Bull Case
$8.00
Bear Case
$1.50
Valuation Basis
Based on a 6x Price/Sales multiple applied to the lower end of projected FY2026 revenue guidance ($78M), assuming a stable estimated share count of ~82.6M ($78M * 6 = $468M market cap / 82.6M shares = $5.67).
Entry Strategy
Dollar-cost average between $2.00-$2.50, considering the recent 20% price drop and potential for short-term volatility. Establish a small position now and add on signs of improved profitability or strong Q1 2026 earnings.
Exit Strategy
Take 50% profit at $6.00, reassess at $8.00. Implement a stop-loss at $1.80 if the stock breaks recent support levels.
Portfolio Allocation
5% for aggressive risk tolerance, given the high-growth potential but also significant financial and execution risks inherent in small-cap biotech.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PLX Financially Healthy?
Valuation
P/E Ratio
26.80
Forward P/E
9.79
PEG Ratio
-1.10
Price/Sales
3.10
Profitability
Operating Margin
-51.10%
Net Margin
-12.50%
Return on Equity
-14.40%
Revenue Growth
-18.47%
EPS
$0.08
Other
Beta (Volatility)
-0.26
Does PLX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The proprietary plant-cell based manufacturing platform and orphan drug exclusivity provide a degree of protection. The strategic partnership with Chiesi solidifies market access. However, durability is limited by patent expiry and the constant threat of new, potentially superior therapies in the biotech space.
Moat Erosion Risks
- •Development of new, more effective or cost-efficient treatments for Fabry or Gaucher disease
- •Patent challenges or eventual expiry of key intellectual property
- •Underperformance or strategic shift from commercial partner Chiesi
PLX Competitive Moat Analysis
Sign up to see competitive advantages
PLX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-Bearish, evidenced by the significant stock price drop following recent announcements, despite positive underlying catalysts.
Institutional Sentiment
Neutral-Negative. No recent analyst upgrades or institutional buying reported. The stock's negative reaction to the latest news suggests skepticism.
Insider Activity (Form 4)
No PLX-specific Form 4 filings reported in the last 90 days (since mid-January 2026).
Options Flow
Normal options activity. No specific unusual options activity or put/call ratio direction was reported.
Earnings Intelligence
Next Earnings
Estimated early-May (Q1 2026 earnings expected before market open, exact date not specified)
Surprise Probability
Medium
Historical Earnings Pattern
The stock reacted negatively to the FY 2025 earnings and guidance (dropping over 20%), indicating that investors are currently sensitive to profitability and past performance, even with positive forward-looking catalysts.
Key Metrics to Watch
Competitive Position
Top Competitor
Sanofi (Fabrazyme) / Takeda (Replagal)
Market Share Trend
Gaining ground from a small base in the Fabry disease market with Elfabrio's expanded EU approval and new dosing, competing against established players.
Valuation vs Peers
Not enough data to provide a detailed comparison, but PLX likely trades at a discount to established, profitable rare-disease biotechs given its early-stage profitability profile.
Competitive Advantages
- •Proprietary ProCellEx plant-cell expression platform for enzyme production
- •Differentiated product profile (e.g., every-4-weeks dosing for Elfabrio)
- •Strong global commercialization partnership with Chiesi
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PLX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (expected before market open, exact date not specified)
- •Continued commercial rollout and adoption of Elfabrio in the EU with new dosing regimen
- •Confirmation of $50M cash balance by April 2026, post milestone payment
Medium-Term (6-18 months)
- •Further updates on Phase 2 PRX-115 enrollment and interim data readout potential
- •Expansion of Elfabrio into new geographic markets or additional indications
- •New strategic partnerships or licensing agreements
Long-Term (18+ months)
- •Top-line results for PRX-115 Phase 2 trial (expected H2 2027)
- •Achievement of sustained profitability and positive free cash flow
- •Pipeline expansion with new candidates leveraging ProCellEx platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PLX?
- ✓
Acceleration in Elfabrio revenue growth beyond guidance expectations.
- ✓
Demonstrated improvement in gross and operating margins, leading to positive free cash flow.
- ✓
Positive clinical updates or expedited development for the PRX-115 program.
Bull Case Analysis
See what could go right with Premium
Competing with PLX
See how Protalix Biotherapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Protalix Biotherapeutics Inc PLX | $166.8M | 7.3 | 26.8 | $52.7M | -12.5% | -18.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Protalix Biotherapeutics Inc Makes Money
Protalix Biotherapeutics is a biotechnology company that develops and sells plant-cell expressed recombinant therapeutic proteins primarily for rare genetic diseases. Their main revenue comes from two enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease. Protalix partners with Chiesi Global Rare Diseases, which handles the global commercialization and distribution of these drugs. In return, Protalix receives a share of product sales and milestone payments tied to regulatory approvals and commercial achievements. Their unique ProCellEx manufacturing platform is key to producing their therapies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Protalix Biotherapeutics Inc (PLX)?
As of April 13, 2026, Protalix Biotherapeutics Inc has a DVR Score of 7.3 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Protalix Biotherapeutics Inc?
Protalix Biotherapeutics Inc's market capitalization is approximately $166.8M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Protalix Biotherapeutics Inc use?
PLX is the ticker symbol for Protalix Biotherapeutics Inc. The company trades on the ASE.
What is the risk level for PLX stock?
Our analysis rates Protalix Biotherapeutics Inc's overall risk as Moderate-Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PLX?
Protalix Biotherapeutics Inc currently has a price-to-earnings (P/E) ratio of 26.8. This is in line with broader market averages.
Is Protalix Biotherapeutics Inc's revenue growing?
Protalix Biotherapeutics Inc has reported revenue growth of -18.5%. Revenue has been declining, which warrants closer examination.
Is PLX stock profitable?
Protalix Biotherapeutics Inc has a profit margin of -12.5%. The company is currently unprofitable.
How often is the PLX DVR analysis updated?
Our AI-powered analysis of Protalix Biotherapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 13, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PLX (Protalix Biotherapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.